Fundamentos en el uso actual de los beta-bloqueadores como tratamiento de la hipertensión arterial
DOI:
https://doi.org/10.26820/recimundo/7.(2).jun.2023.365-382Keywords:
Antagonistas de Receptores Adrenérgicos Beta 1, Hipertensión, Tratamiento Farmacológico, Usos TerapéuticosAbstract
Este estudio se enfoca en el uso contemporáneo de los betabloqueantes como herramientas terapéuticas en el tratamiento de la hipertensión arterial, con una atención particular en los antagonistas de los receptores adrenérgicos beta 1. Objetivo: Proporcionar una evaluación actualizada y exhaustiva de los fundamentos que respaldan el uso de los betabloqueantes en la gestión de la hipertensión, y cotejar su eficacia y seguridad con otros agentes antihipertensivos. Métodos: Se llevó a cabo un análisis retrospectivo descriptivo a través de una revisión sistemática de literatura. Se implementó una búsqueda comprensiva en diversas bases de datos, incluyendo LILACS, Cochrane, PubMed, Web Of Science, Scopus y ELSEVIER, utilizando palabras clave relevantes: Antagonistas de Receptores Adrenérgicos Beta 1, Hipertensión, Tratamiento Farmacológico, y Usos Terapéuticos. Resultados: A pesar de una eficacia en la reducción de la presión arterial comparable a otros agentes antihipertensivos, los betabloqueantes demostraron una efectividad menor en la prevención de eventos cardiovasculares y la reducción de la morbimortalidad, en contraste con medicamentos como los inhibidores de la enzima convertidora de angiotensina (IECA) y los antagonistas de los receptores de angiotensina II (ARA II). Se observaron también efectos secundarios, entre ellos la fatiga, mareos y disfunción sexual. Conclusiones: Los betabloqueantes pueden seguir siendo una alternativa terapéutica viable en la gestión de la hipertensión, particularmente en pacientes con enfermedades cardíacas coexistentes, como la enfermedad coronaria y la insuficiencia cardíaca. No obstante, la selección de estos agentes debe estar fundamentada en una evaluación individual del paciente, teniendo en cuenta los posibles efectos adversos. Implicaciones: Este estudio amplía el conocimiento sobre la eficacia y seguridad de los betabloqueantes en el tratamiento de la hipertensión arterial, proporcionando información valiosa para la práctica clínica y orientando investigaciones futuras en el campo de la hipertensión arterial.Downloads
References
Brouwers S, Sudano I, Kokubo Y, Sulaica EM. Arterial hypertension. The Lancet [Internet]. 2021 Jul 17 [cited 2023 Jun 24];398(10296):249–61. Available from: https://www.thelancet.com/article/S0140-6736%2821%2900221-X/fulltext
Darabont RO. Arterial hypertension-the timeline of a concept. J Hypertens Res [Internet]. 2022;8(1):9–13. Available from: www.hypertens.org/jhr
Nolde JM, Beaney T, Carnagarin R, Schutte AE, Poulter NR, Schlaich MP. Global Impact of Different Blood Pressure Thresholds in 4 021 690 Participants of the May Measurement Month Initiative. Hypertension [Internet]. 2022 Jul 1 [cited 2023 Jul 5];79(7):1497–505. Available from: https://www.ahajournals.org/doi/full/10.1161/HYPERTENSIONAHA.122.19144
Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta-blockers for hypertension. Cochrane Database of Systematic Reviews [Internet]. 2017 Jan 20 [cited 2023 Jul 11];2017(1). Available from: https://www.cochranelibrary.com/es/cdsr/doi/10.1002/14651858.CD002003.pub5/epdf/full
Lee H, Yano Y, Cho SMJ, Heo JE, Kim DW, Park S, et al. Adherence to Antihypertensive Medication and Incident Cardiovascular Events in Young Adults with Hypertension. Hypertension [Internet]. 2021 Apr 1 [cited 2023 Jul 11];77(4):1341–9. Available from: https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.120.16784
Vögele A, Johansson T, Renom-Guiteras A, Reeves D, Rieckert A, Schlender L, et al. Effectiveness and safety of beta blockers in the management of hypertension in older adults: A systematic review to help reduce inappropriate prescribing. BMC Geriatr [Internet]. 2017 Oct 16 [cited 2023 Jul 11];17. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647554/
Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. J Am Coll Cardiol [Internet]. 2022 Dec 20 [cited 2023 Jul 15];80(25):2361–71. Available from: https://doi.org/10.1016/j.jacc.2022.11.005
Crea F. The burden of cardiovascular risk factors: A global perspective. Eur Heart J [Internet]. 2022 Aug 7 [cited 2023 Jul 15];43(30):2817–20. Available from: https://academic.oup.com/eurheartj/article/43/30/2817/6655908?login=false
Lindstrom M, DeCleene N, Dorsey H, Fuster V, Johnson CO, LeGrand KE, et al. Global Burden of Cardiovascular Diseases and Risks Collaboration, 1990-2021. J Am Coll Cardiol [Internet]. 2022 Dec 12;80(25). Available from: https://doi.Org/10.1016/j.jacc.2022.ll.001
Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. The Lancet [Internet]. 2021 Sep;398(10304):957–80. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673621013301
Wyss F, Valdez O, Camafort M, Coca A. Comprehensive Therapeutic Approach to Hypertension. Recommendations for Central America and the Caribbean. Hipertens Riesgo Vasc [Internet]. 2023 Jan 1 [cited 2023 Jul 16];40(1):40–7. Available from: https://doi.org/10.1016/j.hipert.2022.05.004
Camafort M, Alcocer L, Coca A, Lopez-Lopez JP, López-Jaramillo P, Ponte-Negretti CI, et al. Latin-American Ambulatory Blood Pressure Registry (MAPA-LATAM): An urgent need. Rev Clin Esp [Internet]. 2021;221:547–52. Available from: www.elsevier.es/rce
Carlos Zevallos J, Zea E, Daniela Valdivieso P, Vásconez J. RESUMEN EJECUTIVO ENCUESTA STEPS [Internet]. 2020. Quito; 2020 [cited 2023 Jul 16]. Available from: https://www.salud.gob.ec/wp-content/uploads/2020/10/RESUMEN-EJECUTIVO-ENCUESTA-STEPS-final.pdf
Ma J, Chen X. Advances in pathogenesis and treatment of essential hypertension. Front Cardiovasc Med [Internet]. 2022 Oct 14 [cited 2023 Jul 23];9. Available from: https://doi.org/10.3389/fcvm.2022.1003852
Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. Arterial hypertension: New concepts in diagnosis and treatment? Eur Heart J [Internet]. 2020 Sep 1 [cited 2023 Jul 23];61(33):145–7. Available from: https://doi.org/10.1093/eurheartj/ehy339
Götzinger F, Kunz M, Lauder L, Böhm M, Mahfoud F. Arterial Hypertension—clinical trials update 2023. Hypertension Research [Internet]. 2023 [cited 2023 Jul 23]; Available from: https://doi.org/10.1038/s41440-023-01359-y
Harrison DG, Coffman TM, Wilcox CS. Pathophysiology of Hypertension: The Mosaic Theory and Beyond. Circ Res [Internet]. 2021 Apr 2 [cited 2023 Jul 26];128(7):847–63. Available from: https://doi.org/10.1161/CIRCRESAHA.121.318082
Helena M, Foivos-¡constantinos S, Georgia L, Georgia T, Panagiotis S. The Genetic Basis of Hypertension. Journal of Medicine and Healthcare [Internet]. 2021 May 13 [cited 2023 Jul 26];3(2):1–6. Available from: https://www.onlinescientificresearch.com/articles/the-genetic-basis-of-hypertension.pdf
Natío T, Inoue K, Sonehara K, Baba R, Kodama T, Otagaki Y, et al. Genetic Risk of Primary Aldosteronism and Its Contribution to Hypertension: A Cross-Ancestry Meta-Analysis of Genome-Wide Association Studies. Circulation [Internet]. 2023 Apr 4;147:1097–109. Available from: https://www.ahajournals.Org/doi/suppl/10.1161/CIRCULATI0NAHA.122.062349.
Babaee E, Tehrani-Banihashem A, Eshrati B, Purabdollah M, Nojomi M. How Much Hypertension is Attributed to Overweight, Obesity, and Hyperglycemia Using Adjusted Population Attributable Risk in Adults? Int J Hypertens [Internet]. 2020 Aug 14 [cited 2023 Jul 26];2020:1–7. Available from: https://doi.org/10.1155/2020/4273456
Van Oort S, Beulens JWJ, Van Ballegooijen AJ, Grobbee DE, Larsson SC. Association of Cardiovascular Risk Factors and Lifestyle Behaviors with Hypertension: A Mendelian Randomization Study. Hypertension [Internet]. 2020 Dec 1 [cited 2023 Jul 26];76(6):1971–9. Available from: https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.120.15761
Maruhashi T, Higashi Y. Current topic of vascular function in hypertension. Hypertension Research [Internet]. 2023 Mar 1 [cited 2023 Jul 26];46(3):630–7. Available from: https://doi.org/10.1038/s41440-022-01147-0
Reckelhoff JF. Mechanisms of sex and gender differences in hypertension. J Hum Hypertens [Internet]. 2023 Feb 16 [cited 2023 Jul 26]; Available from: https://doi.org/10.1038/s41371-023-00810-4
Adua E. Decoding the mechanism of hypertension through multiomics profiling. J Hum Hypertens [Internet]. 2023 Apr 1 [cited 2023 Jul 26];37(4):253–64. Available from: https://doi.org/10.1038/s41371-022-00769-8
Mancia Chairperson G, Kreutz Co-Chair R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens [Internet]. 2023 Jun 21 [cited 2023 Jul 23]; Available from: https://doi.org/10.1097/HJH.0000000000003480
Molero Y, Kaddoura S, Kuja-Halkola R, Larsson H, Lichtenstein P, D’Onofrio BM, et al. Associations between β-blockers and psychiatric and behavioural outcomes: A population-based cohort study of 1.4 million individuals in Sweden. PLoS Med. 2023 Jan 1;20(1).
Martinez-Ríos E, Montesinos L, Alfaro-Ponce M, Pecchia L. A review of machine learning in hypertension detection and blood pressure estimation based on clinical and physiological data. Vol. 68, Biomedical Signal Processing and Control. Elsevier Ltd; 2021.
Bruning R, Dykes H, Jones TW, Wayne NB, Sikora Newsome A. Beta-Adrenergic Blockade in Critical Illness. Vol. 12, Frontiers in Pharmacology. Frontiers Media S.A.; 2021.
Senussi MH. Beta-Blockers in the Critically Ill: Friend or Foe? Vol. 78, Journal of the American College of Cardiology. Elsevier Inc.; 2021. p. 1012–4.
Esler M, Kjeldsen SE, Pathak A, Grassi G, Kreutz R, Mancia G. Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified. Vol. 31, Blood Pressure. Taylor and Francis Ltd.; 2022. p. 210–24.
Bruning R, Dykes H, Jones TW, Wayne NB, Sikora Newsome A. Beta-Adrenergic Blockade in Critical Illness. Vol. 12, Frontiers in Pharmacology. Frontiers Media S.A.; 2021.
Tain YL, Hsu CN. Oxidative Stress-Induced Hypertension of Developmental Origins: Preventive Aspects of Antioxidant Therapy. Vol. 11, Antioxidants. MDPI; 2022.
Mansbart F, Kienberger G, Sönnichsen A, Mann E. Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing. BMC Geriatr. 2022 Dec 1;22(1).
Greaney JL, Darling AM, Mogle J, Saunders EFH. Microvascular β-Adrenergic Receptor-Mediated Vasodilation Is Attenuated in Adults with Major Depressive Disorder. Hypertension. 2022 May 1;79(5):1091–100.
Prabha N, Chhabra N, Arora R. Beta-blockers in dermatology. Vol. 83, Indian Journal of Dermatology, Venereology and Leprology. Wolters Kluwer Medknow Publications; 2017. p. 399–407.
Chhatar S, Lal G. Role of adrenergic receptor signalling in neuroimmune communication. Current Research in Immunology [Internet]. 2021 Jan 1 [cited 2023 Jul 28];2:202–17. Available from: https://doi.org/10.1016/j.crimmu.2021.11.001
Guo QH, Zhu ZM, Feng YQ, Lin JX, Wang JG. Blood pressure lowering effects of β-blockers as add-on or combination therapy: A meta-analysis of randomized controlled trials. J Clin Hypertens [Internet]. 2023 Mar 1 [cited 2023 Jul 29];25(3):227–37. Available from: https://doi.org/10.1111/jch.14616
Čižmáriková R, Habala L, Valentová J, Markuliak M. Survey of pharmacological activity and pharmacokinetics of selected β-adrenergic blockers in regard to their stereochemistry. Applied Sciences (Switzerland) [Internet]. 2019 Feb 13 [cited 2023 Jul 29];9(4). Available from: https://doi.org/10.3390/app9040625
Rysz J, Franczyk B, Rysz-Górzyńska M, Gluba-Brzózka A. Pharmacogenomics of hypertension treatment. Int J Mol Sci [Internet]. 2020 Jul 1 [cited 2023 Jul 29];21(13):1–26. Available from: https://doi.org/10.3390/ijms21134709
Vasanthakumar N. Beta-Adrenergic Blockers as a Potential Treatment for COVID-19 Patients. BioEssays. 2020 Nov 1;42(11).
